Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report)’s stock price fell 3.5% during mid-day trading on Wednesday . The stock traded as low as $3.25 and last traded at $3.35. 4,633 shares traded hands during trading, a decline of 73% from the average session volume of 17,048 shares. The stock had previously closed at $3.47.
Analyst Ratings Changes
Separately, Guggenheim initiated coverage on Nanobiotix in a research report on Wednesday, August 28th. They set a “buy” rating and a $12.00 price target for the company.
Get Our Latest Report on Nanobiotix
Nanobiotix Stock Performance
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
- Five stocks we like better than Nanobiotix
- 3 Small Caps With Big Return Potential
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- With Risk Tolerance, One Size Does Not Fit All
- 3 Penny Stocks Ready to Break Out in 2025
- How Technical Indicators Can Help You Find Oversold Stocks
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
